Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02706328 2015-04-21
CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE
COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
Field of the Invention
The present invention relates to certain cycloalkyloxy- and
heterocycloalkyloxypyridine compounds, pharmaceutical compositions containing
them, and methods of using them for the treatment of disease states,
disorders,
and conditions mediated by the histamine H3 receptor.
Background of the Invention
The histamine H3 receptor was first described as a presynaptic
autoreceptor in the central nervous system (CNS) (Arrang, J.-M. et al. Nature
1983, 302, 832-837) controlling the synthesis and release of histamine. The
histamine H3 receptor is primarily expressed in the mammalian central nervous
system (CNS), with some minimal expression in peripheral tissues such as
vascular smooth muscle.
Thus, several indications for histamine H3 antagonists and inverse agonists
have been proposed based on animal pharmacology and other experiments with
known histamine H3 antagonists (e.g. thioperamide). (See: Krause et al. and
Phillips et al. in "The Histamine H3 Receptor-A Target for New Drugs", Leurs,
R.
and Timmerman, H., (Eds.), Elsevier, 1998, pp. 175-196 and 197-222; Morisset,
S.
et al. Nature 2000, 408, 860-864.) These include conditions such as cognitive
disorders, sleep disorders, psychiatric disorders, and other disorders.
For example, histamine H3 antagonists have been shown to have
pharmacological activity relevant to several key symptoms of depression,
including
sleep disorders (e.g. sleep disturbances, fatigue, and lethargy) and cognitive
difficulties (e.g. memory and concentration impairment), as described above.
For
reviews, see: Bonaventure, P. et al. Biochem. Pharm. 2007, 73, 1084-1096;
Letavic, M.A. et al. Prog. Med. Chem. 1996, 44, 181-206. There remains a need
1
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
for potent histamine H3 receptor modulators with desirable pharmaceutical
properties.
Various literature publications describe small-molecule histamine H3
receptor inhibitors: PCT Intl. Appl. Publ. WO 2005/040144 (diazepanyl
derivatives); U.S. Pat. Appl. Publ. US 2007/0167435 (phenoxypiperidines); U.S.
Pat. Appl. Publ. US 2005/222151 (non-imidazole heterocyclic compounds); U.S.
Pat. Appl. Publ. US 2007/219240 (N-substituted-azacyclylamines); U.S. Pat.
Appl.
Publ. US 2006/0052597 (aryloxyalkylamine derivatives); U.S. Pat. Appl. Publ.
US
2006/0178375 (heteroaryloxy nitrogen-containing derivatives); U.S. Pat. Appl.
11/753,607 (Attorney Docket No. PRD2678); and U.S. Pat. Appl. 11/766,144
(Attorney Docket No. PRD2686).
Summary of the Invention
Certain cycloalkyloxy- and heterocycloalkyloxypyridine derivatives have
now been found to have histamine H3 receptor modulating activity. Thus, the
invention is directed to the general and preferred embodiments defined,
respectively, by the independent and dependent claims appended hereto, which
are incorporated by reference herein.
In one general aspect the invention relates to a compound of the following
Formula (I):
Di R2
, ......vm ........-.....,
m 1 I (I)
r,11r)(*1
0
wherein
R1 is -01_5a1ky1 or a saturated cycloalkyl group;
m is 1 or 2;
R2 is -H or ¨OCHR3R4;
where R3 is ¨H; and
R4 is a cycloalkyl or heterocycloalkyl ring, unsubstituted or substituted with
-Ci_4alkyl or acetyl;
2
CA 02706328 2015-04-21
or, R3 and R4 taken together with the carbon to which they are attached form a
cycloalkyl or heterocycloalkyl ring, unsubstituted or substituted with -
Ci_aalkyl
or acetyl;
X is N or CH; and
Y is N or CRa;
where Ra is ¨H, ¨OCHR3R4, -CH2NRbRc, -ON, -CO2C1_4alkyl, -CO2H,
or -CONRbRc;
Rb and Rc are each independently -H or -Ci_aalkyl;
with the proviso that one of X and Y is N and one of R2 and Ra is ¨OCHR3R4;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug,
or a
pharmaceutically active metabolite thereof.
In a further general aspect, there is provided pharmaceutical compositions
each comprising: (a) an effective amount of a compound of Formula (I) or a
pharmaceutically acceptable salt thereof; and (b) a pharmaceutically
acceptable
excipient.
In another general aspect, there is provided use of an effective amount or use
in the manufacture of a medicament of a compound of Formula (I), or a
pharmaceutically acceptable salt thereof for treating a subject suffering from
or
diagnosed with a disease, disorder, or medical condition mediated by histamine
H3
receptor activity.
In certain preferred embodiments, the disease, disorder, or medical condition
is selected from: cognitive disorders, sleep disorders, psychiatric disorders,
and other
disorders.
Additional embodiments, features, and advantages of the invention will be
apparent from the following detailed description and through practice of the
invention.
3
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
Detailed Description
The invention may be more fully appreciated by reference to the following
description, including the following glossary of terms and the concluding
examples.
For the sake of brevity, the disclosures of the publications, including
patents, cited
in this specification are herein incorporated by reference.
As used herein, the terms "including", "containing" and "comprising" are
used herein in their open, non-limiting sense.
The term "alkyl" refers to a straight- or branched-chain alkyl group having
from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include
methyl
(Me, which also may be structurally depicted by a bond "I"), ethyl (Et), n-
propyl,
isopropyl (iPr), butyl (Bu or n-Bu), isobutyl (iBu), sec-butyl, tert-butyl (t-
Bu), pentyl,
isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the
ordinary skill in
the art and the teachings provided herein would be considered equivalent to
any
one of the foregoing examples.
The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic
carbocycle having from 3 to 10 ring atoms per carbocycle. Illustrative
examples of
cycloalkyl groups include the following entities, in the form of properly
bonded
moieties:
>, ,
n, 0, 0, 0, r, $ , = , and fel
A "heterocycloalkyl" refers to a monocyclic ring structure that is saturated
or
partially saturated and has from 4 to 7 ring atoms per ring structure selected
from
carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and
sulfur. The ring structure may optionally contain up to two oxo groups on
sulfur
ring members. Illustrative entities, in the form of properly bonded moieties,
include:
H H
H H
N N 0 1
N 0
rial r? \ _______________ \ __ / , 0, HN-NH, \ 2, CN,CN,
4
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
S
0 0 0 0\// 0 H
N
(NI) , NHI , (NH (NH vr\NI)
, N.-nNH ,and N.¨o =
The term "heteroaryl" refers to a monocyclic, fused bicyclic, or fused
polycyclic aromatic heterocycle (ring structure having ring atoms selected
from
carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and
sulfur) having from 3 to 12 ring atoms per heterocycle. Illustrative examples
of
heteroaryl groups include the following entities, in the form of properly
bonded
moieties:
71\1 7s (N? N
N N
N0
-N rN
, N , , , N ,
S,
401 0, , 401 s, \
N ,
1101 N, 401
N N N ,and \N
Those skilled in the art will recognize that the species of cycloalkyl,
heterocycloalkyl, and heteroaryl groups listed or illustrated above are not
exhaustive, and that additional species within the scope of these defined
terms
may also be selected.
The term "halogen" represents chlorine, fluorine, bromine or iodine. The
term "halo" represents chloro, fluoro, bromo or iodo.
The term "substituted" means that the specified group or moiety bears one
or more substituents. The term "unsubstituted" means that the specified group
bears no substituents. The term "optionally substituted" means that the
specified
group is unsubstituted or substituted by one or more substituents. Where the
term
"substituted" is used to describe a structural system, the substitution is
meant to
5
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
occur at any valency-allowed position on the system. In cases where a
specified
moiety or group is not expressly noted as being optionally substituted or
substituted with any specified substituent, it is understood that such a
moiety or
group is intended to be unsubstituted.
Any formula given herein is intended to represent compounds having
structures depicted by the structural formula as well as certain variations or
forms.
In particular, compounds of any formula given herein may have asymmetric
centers and therefore exist in different enantiomeric forms. All optical
isomers and
stereoisomers of the compounds of the general formula, and mixtures thereof,
are
considered within the scope of the formula. Thus, any formula given herein is
intended to represent a racemate, one or more enantiomeric forms, one or more
diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
Furthermore, certain structures may exist as geometric isomers (i.e., cis and
trans
isomers), as tautomers, or as atropisomers. Additionally, any formula given
herein
is intended to embrace hydrates, solvates, and polymorphs of such compounds,
and mixtures thereof.
Any formula given herein is also intended to represent unlabeled forms as
well as isotopically labeled forms of the compounds. Isotopically labeled
compounds have structures depicted by the formulas given herein except that
one
or more atoms are replaced by an atom having a selected atomic mass or mass
number. Examples of isotopes that can be incorporated into compounds of the
invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous,
fluorine, chlorine, and iodine, such as 2H, 3H, 1103 1303 1403 15N3 1803 1703
31P3 32P3
35, 18F3 36013 125.3
I respectively. Such isotopically labeled compounds are useful in
metabolic studies (preferably with 140), reaction kinetic studies (with, for
example
2H or 3H), detection or imaging techniques [such as positron emission
tomography
(PET) or single-photon emission computed tomography (SPECT)] including drug
or substrate tissue distribution assays, or in radioactive treatment of
patients. In
particular, an 18F or 110 labeled compound may be particularly preferred for
PET
or SPECT studies. Further, substitution with heavier isotopes such as
deuterium
6
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
(i.e., 2H) may afford certain therapeutic advantages resulting from greater
metabolic stability, for example increased in vivo half-life or reduced dosage
requirements. Isotopically labeled compounds of this invention and prodrugs
thereof can generally be prepared by carrying out the procedures disclosed in
the
schemes or in the examples and preparations described below by substituting a
readily available isotopically labeled reagent for a non-isotopically labeled
reagent.
When referring to any formula given herein, the selection of a particular
moiety from a list of possible species for a specified variable is not
intended to
define the moiety for the variable appearing elsewhere. In other words, where
a
variable appears more than once, the choice of the species from a specified
list is
independent of the choice of the species for the same variable elsewhere in
the
formula.
In preferred embodiments of Formula (I), R1 is isopropyl, cyclopropyl,
cyclobutyl, or cyclopentyl. In other preferred embodiments, R1 is cyclopropyl
or
cyclobutyl.
In some embodiments, m is 1. In other embodiments, m is 2.
In some embodiments, X is N. In other embodiments, Y is N.
In some embodiments, R2 is ¨H and Ra is ¨OCHR3R4. In other
embodiments, R2 is ¨OCHR3R4 and Ra is not ¨OCHR3R4.
In some embodiments, R3 is ¨H and R4 is cyclopropyl, cyclocyclobutyl, or 3-
methyl-oxetan-3-yl. In other embodiments, R3 and R4 taken together with the
carbon to which they are attached form cyclobutyl, cyclopentyl, cyclohexyl,
tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothiophenyl,
tetrahydrothiopyranyl, pyrrolidinyl, thiepanyl, piperidinyl, or azepanyl,
unsubstituted
or substituted with methyl, ethyl, isopropyl, or acetyl.
In still other embodiments, ¨OCHR3R4 is tetrahydro-furan-3-yloxy, 3-methyl-
oxetan-3-ylmethoxy, cyclopentyloxy, cyclohexyloxy, tetrahydro-pyran-4-yloxy,
tetrahydro-pyran-3-yloxy, cyclobutyloxy, oxepan-4-yloxy, oxepan-3-yloxy,
cyclobutyl methoxy, cyclopropyl methoxy, tetrahydro-thiophen-3-yloxy,
tetrahydro-
thiopyran-4-yloxy, 1-methyl-pyrrolidin-3-yloxy, 1-acetyl-pyrrolidin-3-yloxyl,
thiepan-
7
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
3-yloxy, thiepan-4-yloxy, 1-methyl-piperidin-4-yloxy, 1-acetyl-piperidin-4-
yloxy, 1-
isopropyl-azepan-4-yloxy, 1-acetyl-azepan-4-yloxy, 1-ethyl-azepan-3-yloxy, or
1-
acetyl-azepan-3-yloxy. In still other embodiments, ¨OCHR3R4 is tetrahydro-
furan-
3-yloxy, 3-methyl-oxetan-3-ylmethoxy, cyclopentyloxy, cyclohexyloxy, or
tetrahydro-pyran-4-yloxy.
In further preferred embodiments, ¨OCHR3R4 is tetrahydro-pyran-4-yloxy
and m is 2.
In certain preferred embodiments, the compound of Formula (I) is selected
from the group consisting of:
Ex. Chemical Name
(4-lsopropyl-piperazin-1 -y1)-[6-(tetrahydro-furan-3-yloxy)-pyridin-3-y1]-
1
methanone;
2
(4-Isopropyl-[i ,4]diazepan-1 -yI)-[6-(tetrahydro-furan-3-yloxy)-pyrid in-3-
yI]-methanone;
(4-Cyclopropy141 ,4]diazepan-1 -yI)-[6-(tetrahydro-furan-3-yloxy)-pyrid in-
3
3-yI]-methanone;
(4-Cyclobuty1-[i ,4]d iazepan-1 -y1)46-(tetrahydro-furan-3-yloxy)-pyrid in-3-
4
yI]-methanone;
(4-Isopropyl-piperazin-1 -y1)46-(3-methyl-oxetan-3-ylmethoxy)-pyrid in-3-
5
yI]-methanone;
6
(4-Isopropyl41 ,4]diazepan-1 -yI)-[6-(3-methyl-oxetan-3-ylmethoxy)-
pyridin-3-y1]-methanone;
(4-Cyclobutyl-[i ,4]diazepan-1 -yI)-(6-cyclopentyloxy-pyrid in-3-yI)-
7
methanone;
8
(4-Cyclobutyl-[i ,4]diazepan-1 -yI)-(6-cyclohexyloxy-pyrid in-3-yI)-
methanone;
(4-Cyclobuty141 ,4]diazepan-1 -yI)-[6-(tetrahydro-pyran-4-yloxy)-pyrid in-3-
9
yI]-methanone;
8
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
6-(4-Cyclopropyl-[1 ,4]diazepane-1 -carbonyl)-3-(tetrahyd ro-fu ran-3-
yloxy)-pyridine-2-carbonitrile;
11
3-Cyclopentyloxy-6-(4-cyclopropyl-[1 ,4]diazepane-1 -carbonyI)-pyrid ine-
2-carbon itrile;
12
3-Cyclohexyloxy-6-(4-cyclopropy141 ,4]diazepane-1 -carbonyl)-pyrid i ne-2-
carbon itrile;
13
(4-Isopropyl-[1 ,4]diazepan-1 -yI)-[6-(tetrahyd ro-pyran-4-yloxy)-pyrid in-3-
yI]-methanone;
14
(4-Cyclopropy1-[1 ,4]diazepan-1 -yI)-[6-(tetrahydro-pyran-4-yloxy)-pyrid in-
3-yI]-methanone;
(4-Cyclopenty1-[1 ,4]diazepan-1 -yI)-[6-(tetrahyd ro-pyran-4-yloxy)-pyrid in-
3-yI]-methanone;
16
(4-Isopropyl-piperazin-1 -y1)[6-(tetrahydro-pyran-4-yloxy)-pyrid in-3-yI]-
methanone;
17
(4-Cyclopropyl-piperazin-1 -y1)46-(tetrahydro-pyran-4-yloxy)-pyrid in-3-yI]-
methanone;
18
(4-Cyclobutyl-piperazin-1 -yI)-[6-(tetrahyd ro-pyran-4-yloxy)-pyrid in-3-yI]-
methanone;
19
(4-Cyclopentyl-piperazin-1 -yI)-[6-(tetrahyd ro-pyran-4-yloxy)-pyrid i n-3-yI]-
methanone;
(4-Cyclobuty141 ,4]diazepan-1 -yI)-[5-(tetrahydro-pyran-4-yloxy)-pyrid in-2-
yI]-methanone;
21
(4-Cyclobuty141 ,4]diazepan-1 -yI)-[6-(tetrahydro-pyran-4-yloxy)-pyrid in-2-
yI]-methanone;
22
(6-Cyclobutoxy-pyridin-3-y1)-(4-cyclobuty1-[1 ,4]diazepan-1 -yI)-
methanone;
23
(4-Cyclobutyl-[1 ,4]diazepan-1 -yI)-[6-(oxepan-4-yloxy)-pyrid in-3-yI]-
methanone;
9
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
24
(4-Cyclobutyl-[1 ,4]d iazepan-1 -y1)-[6-(oxepan-3-yloxy)-pyrid in-3-y1]-
methanone;
(4-Cyclobutyl-[1 ,4]d iazepan-1 -y1)-(6-cyclobutylmethoxy-pyrid in-3-y1)-
methanone;
26
(4-Cyclobutyl-[1 ,4]diazepan-1 -y1)-(6-cyclopropylmethoxy-pyrid in-3-y1)-
methanone;
27
(4-Cyclobuty141 ,4]diazepan-1 -y1)-[6-(tetrahydro-thiophen-3-yloxy)-
pyridin-3-y1]-methanone;
28
(4-Cyclobuty141 ,4]diazepan-1 -y1)-[6-(tetrahydro-th iopyran-4-yloxy)-
pyridin-3-y1]-methanone;
29
(4-Cyclobuty1-[i ,4]diazepan-1-y1)-[6-(1 -methyl-pyrrol id in-3-yloxy)-pyrid
in-
3-y1]-methanone;
1
-{345-(4-Cyclobutyl-[i ,4]diazepane-1 -carbonyl)-pyrid in-2-yloxy]-
pyrrolidin-1-yll-ethanone;
31
(4-Cyclobutyl-[i ,4]diazepan-1 -y1)-[6-(th iepan-3-yloxy)-pyrid in-3-y1]-
methanone;
32
(4-Cyclobuty1-[i ,4]diazepan-1 -y1)-[6-(th iepan-4-yloxy)-pyrid in-3-y1]-
methanone;
(4-Cyclobuty1-[i ,4]diazepan-1-y1)-[6-(1 -methyl-piperid in-4-yloxy)-pyrid in-
33
3-y1]-methanone;
1 -{445-(4-Cyclobuty1-[i ,4]diazepane-1 -carbony1)-pyrid in-2-yloxy]-
34
piperidin-1-yll-ethanone;
(4-Cyclobuty1-[i ,4]diazepan-1 -y1)-[6-(1 -isopropyl-azepan-4-yloxy)-
pyridin-3-y1]-methanone;
1
36 -{445-(4-Cyclobuty1-[i ,4]diazepane-1 -carbonyl)-pyrid in-2-
yloxy]-
azepan-1 -ylyethanone;
(4-Cyclobutyl-[i ,4]diazepan-1-y1)-[6-(1 -ethyl-azepan-3-yloxy)-pyridin-3-
37
y1]-methanone; and
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
38
1-{345-(4-Cyclobutyl-[1,4]diazepane-1-carbonyl)-pyridin-2-yloxy]-
azepan-1-yll-ethanone; and
(4-Cyclopropyl-piperazin-1-y1)46-(tetrahydro-pyran-3-yloxy)-pyridin-3-y1]-
methanone;
(4-Cyclobutyl-[1,4]diazepan-1-y1)46-(tetrahydro-pyran-4-yloxy)-pyridin-3-
yI]-methanone=HCI
and pharmaceutically acceptable salts thereof.
The invention includes also pharmaceutically acceptable salts of the
compounds of Formula (I), preferably of those described above and of the
specific
compounds exemplified herein, and methods of treatment using such salts.
5 A
"pharmaceutically acceptable salt" is intended to mean a salt of a free
acid or base of a compound represented by Formula (I) that is non-toxic,
biologically tolerable, or otherwise biologically suitable for administration
to the
subject. See, generally, S.M. Berge, et al., "Pharmaceutical Salts", J. Pharm.
Sci.,
1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection,
and
10 Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Examples
of
pharmaceutically acceptable salts are those that are pharmacologically
effective
and suitable for contact with the tissues of patients without undue toxicity,
irritation,
or allergic response.
A compound of Formula (I) may possess a sufficiently acidic group, a
15 sufficiently basic group, or both types of functional groups, and
accordingly react
with a number of inorganic or organic bases, and inorganic and organic acids,
to
form a pharmaceutically acceptable salt. Examples of pharmaceutically
acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites,
bisulfites,
phosphates, monohydrogen-phosphates, dihydrogenphosphates,
20 metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates,
propionates, decanoates, caprylates, acrylates, formates, isobutyrates,
caproates,
heptanoates, propiolates, oxalates, malonates, succinates, suberates,
sebacates,
fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates,
chlorobenzoates, methyl benzoates, din itrobenzoates, hydroxybenzoates,
11
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates,
phenylpropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates,
glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-
sulfonates, naphthalene-2-sulfonates, and mandelates.
If the compound of Formula (I) contains a basic nitrogen, the desired
pharmaceutically acceptable salt may be prepared by any suitable method
available in the art, for example, treatment of the free base with an
inorganic acid,
such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid,
nitric
acid, boric acid, phosphoric acid, and the like, or with an organic acid, such
as
acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid,
ascorbic
acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric
acid,
fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid,
salicylic acid,
oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic
acid or
galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid,
or
tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an
aromatic
acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic
acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid,
methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids
such
as those given as examples herein, and any other acid and mixture thereof that
are regarded as equivalents or acceptable substitutes in light of the ordinary
level
of skill in this technology.
If the compound of Formula (I) is an acid, such as a carboxylic acid or
sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by
any suitable method, for example, treatment of the free acid with an inorganic
or
organic base, such as an amine (primary, secondary or tertiary), an alkali
metal
hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases
such
as those given as examples herein, and any other base and mixture thereof that
are regarded as equivalents or acceptable substitutes in light of the ordinary
level
of skill in this technology. Illustrative examples of suitable salts include
organic
salts derived from amino acids, such as glycine and arginine, ammonia,
12
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic
amines, such as benzylamines, pyrrolidines, piperidine, morpholine, and
piperazine, and inorganic salts derived from sodium, calcium, potassium,
magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
The invention also relates to pharmaceutically acceptable prodrugs of the
compounds of Formula (I), and treatment methods employing such
pharmaceutically acceptable prodrugs. The term "prodrug" means a precursor of
a designated compound that, following administration to a subject, yields the
compound in vivo via a chemical or physiological process such as solvolysis or
enzymatic cleavage, or under physiological conditions (e.g., a prodrug on
being
brought to physiological pH is converted to the compound of Formula (I)). A
"pharmaceutically acceptable prodrug" is a prodrug that is non-toxic,
biologically
tolerable, and otherwise biologically suitable for administration to the
subject.
Illustrative procedures for the selection and preparation of suitable prodrug
derivatives are described, for example, in "Design of Prodrugs", ed. H.
Bundgaard,
Elsevier, 1985.
Examples of prodrugs include compounds having an amino acid residue, or
a polypeptide chain of two or more (e.g., two, three or four) amino acid
residues,
covalently joined through an amide or ester bond to a free amino, hydroxy, or
carboxylic acid group of a compound of Formula (I). Examples of amino acid
residues include the twenty naturally occurring amino acids, commonly
designated
by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine,
isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric
acid,
citrulline homocysteine, homoserine, ornithine and methionine sulfone.
Additional types of prodrugs may be produced, for instance, by derivatizing
free carboxyl groups of structures of Formula (I) as amides or alkyl esters.
Examples of amides include those derived from ammonia, primary C1_6a1ky1
amines and secondary di(C1_6a1ky1) amines. Secondary amines include 5- or 6-
membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides
include those that are derived from ammonia, C1_3a1ky1 primary amines, and
di(Ci_
13
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
2alkyl)amines. Examples of esters of the invention include C1_7a1ky1,
C5_7cycloalkyl,
phenyl, and phenyl(Ci_6alkyl) esters. Preferred esters include methyl esters.
Prodrugs may also be prepared by derivatizing free hydroxy groups using groups
including hemisuccinates, phosphate esters, dimethylaminoacetates, and
phosphoryloxymethyloxycarbonyls, following procedures such as those outlined
in
Adv. Drug Delivery Rev. 1996, 19, 115. Carbamate derivatives of hydroxy and
amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters,
and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization
of
hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl
group may be an alkyl ester, optionally substituted with one or more ether,
amine,
or carboxylic acid functionalities, or where the acyl group is an amino acid
ester as
described above, is also useful to yield prodrugs. Prodrugs of this type may
be
prepared as described in J. Med. Chem. 1996, 39, 10. Free amines can also be
derivatized as amides, sulfonamides or phosphonamides. All of these prodrug
moieties may incorporate groups including ether, amine, and carboxylic acid
functional ities.
The present invention also relates to pharmaceutically active metabolites of
the compounds of Formula (I), which may also be used in the methods of the
invention. A "pharmaceutically active metabolite" means a pharmacologically
active product of metabolism in the body of a compound of Formula (I) or salt
thereof. Prodrugs and active metabolites of a compound may be determined
using routine techniques known or available in the art. See, e.g., Bertolini
et al., J.
Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86(7), 765-
767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv. Drug Res. 1984,
13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen,
Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-
Larsen, et al., eds., Harwood Academic Publishers, 1991).
The compounds of Formula (I) and their pharmaceutically acceptable salts,
pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites
of
the present invention are useful as modulators of the histamine H3 receptor in
the
14
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
methods of the invention. As such modulators, the compounds may act as
antagonists, agonists, or inverse agonists. "Modulators" include both
inhibitors
and activators, where "inhibitors" refer to compounds that decrease, prevent,
inactivate, desensitize or down-regulate histamine H3 receptor expression or
activity, and "activators" are compounds that increase, activate, facilitate,
sensitize, or up-regulate histamine H3 receptor expression or activity.
The term "treat" or "treating" as used herein is intended to refer to
administration of an active agent or composition of the invention to a subject
for
the purpose of effecting a therapeutic or prophylactic benefit through
modulation of
histamine H3 receptor activity. Treating includes reversing, ameliorating,
alleviating, inhibiting the progress of, lessening the severity of, or
preventing a
disease, disorder, or condition, or one or more symptoms of such disease,
disorder or condition mediated through modulation of histamine H3 receptor
activity. The term "subject" refers to a mammalian patient in need of such
treatment, such as a human.
Accordingly, the invention relates to methods of using the compounds
described herein to treat subjects diagnosed with or suffering from a disease,
disorder, or condition mediated by histamine H3 receptor activity, such as:
cognitive disorders, sleep disorders, psychiatric disorders, and other
disorders.
Symptoms or disease states are intended to be included within the scope of
"medical conditions, disorders, or diseases."
Cognitive disorders include, for example, dementia, Alzheimer's disease
(Panula, P. et al., Soc. Neurosci. Abstr. 1995, 21, 1977), cognitive
dysfunction,
mild cognitive impairment (pre-dementia), attention deficit hyperactivity
disorders
(ADHD), attention-deficit disorders, and learning and memory disorders
(Barnes,
J.C. et al., Soc. Neurosci. Abstr. 1993, 19, 1813). Learning and memory
disorders
include, for example, learning impairment, memory impairment, age-related
cognitive decline, and memory loss. H3 antagonists have been shown to improve
memory in a variety of memory tests, including the elevated plus maze in mice
(Miyazaki, S. et al. Life Sci. 1995, 57(23), 2137-2144), a two-trial place
recognition
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
task (Orsetti, M. et al. Behav. Brain Res. 2001, 124(2), 235-242), the passive
avoidance test in mice (Miyazaki, S. et al. Meth. Find. Exp. Clin. Pharmacol.
1995,
17(10), 653-658) and the radial maze in rats (Chen, Z. Acta Pharmacol. Sin.
2000,
21(10), 905-910). Also, in the spontaneously hypertensive rat, an animal model
for the learning impairments in attention-deficit disorders, H3 antagonists
were
shown to improve memory (Fox, G.B. et al. Behav. Brain Res. 2002, 131(1-2),
151-161).
Sleep disorders include, for example, insomnia, disturbed sleep, narcolepsy
(with or without associated cataplexy), cataplexy, disorders of sleep/wake
homeostasis, idiopathic somnolence, excessive daytime sleepiness (EDS),
circadian rhythm disorders, fatigue, lethargy, jet lag (phase delay), and REM-
behavioral disorder. Fatigue and/or sleep impairment may be caused by or
associated with various sources, such as, for example, sleep apnea,
perimenopausal hormonal shifts, Parkinson's disease, multiple sclerosis (MS),
depression, chemotherapy, or shift work schedules.
Psychiatric disorders include, for example, schizophrenia (Schlicker, E. and
Marr, I., Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 353, 290-294),
including
cognitive deficits and negative symptoms associated with schizophrenia,
bipolar
disorders, manic disorders, depression (Lamberti, C. et al. Br. J. Pharmacol.
1998,
123(7), 1331-1336; Perez-Garcia, C. et al. Psychopharmacology 1999, 142(2),
215-220) (Also see: Stark, H. et al., Drugs Future 1996, 21(5), 507-520; and
Leurs, R. et al., Prog. Drug Res. 1995, 45, 107-165 and references cited
therein.),
including bipolar depression, obsessive-compulsive disorder, and post-
traumatic
stress disorder.
Other disorders include, for example, motion sickness, vertigo (e.g. vertigo
or benign postural vertigo), tinitus, epilepsy (Yokoyama, H. et al., Eur. J.
Pharmacol. 1993, 234, 129-133), migraine, neurogenic inflammation, neuropathic
pain, Down Syndrome, seizures, eating disorders (Machidori, H. et al., Brain
Res.
1992, 590, 180-186), obesity, substance abuse disorders, movement disorders
16
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
(e.g. restless legs syndrome), and eye-related disorders (e.g. macular
degeneration and retinitis pigmentosis).
Particularly, as modulators of the histamine H3 receptor, the compounds of
the present invention are useful in the treatment or prevention of depression,
disturbed sleep, narcolepsy, fatigue, lethargy, cognitive impairment, memory
impairment, memory loss, learning impairment, attention-deficit disorders, and
eating disorders.
In treatment methods according to the invention, an effective amount of at
least one compound according to the invention is administered to a subject
suffering from or diagnosed as having such a disease, disorder, or condition.
An
"effective amount" means an amount or dose sufficient to generally bring about
the
desired therapeutic or prophylactic benefit in patients in need of such
treatment for
the designated disease, disorder, or condition. Effective amounts or doses of
the
compounds of the present invention may be ascertained by routine methods such
as modeling, dose escalation studies or clinical trials, and by taking into
consideration routine factors, e.g., the mode or route of administration or
drug
delivery, the pharmacokinetics of the compound, the severity and course of the
disease, disorder, or condition, the subject's previous or ongoing therapy,
the
subject's health status and response to drugs, and the judgment of the
treating
physician. An example of a dose is in the range of from about 0.001 to about
200
mg of compound per kg of subject's body weight per day, preferably about 0.01
to
100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units
(e.g.,
BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage
amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
Once improvement of the patient's disease, disorder, or condition has
occurred, the dose may be adjusted for preventative or maintenance treatment.
For example, the dosage or the frequency of administration, or both, may be
reduced as a function of the symptoms, to a level at which the desired
therapeutic
or prophylactic effect is maintained. Of course, if symptoms have been
alleviated
17
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
to an appropriate level, treatment may cease. Patients may, however, require
intermittent treatment on a long-term basis upon any recurrence of symptoms.
In addition, the compounds of the invention may be used in combination
with additional active ingredients in the treatment of the above conditions.
In an
exemplary embodiment, additional active ingredients are those that are known
or
discovered to be effective in the treatment of conditions, disorders, or
diseases
mediated by histamine H3 receptor activity or that are active against another
target
associated with the particular condition, disorder, or disease, such as H1
receptor
antagonists, H2 receptor antagonists, H4 receptor antagonists, topiramate, and
neurotransmitter modulators such as serotonin-norepinephrine reuptake
inhibitors,
selective serotonin reuptake inhibitors (SSR15), noradrenergic reuptake
inhibitors,
non-selective serotonin re-uptake inhibitors (NSSR15), acetylcholinesterase
inhibitors (such as tetrahydroaminoacridine, donepezil, rivastigmine, or
galantamine), or modafinil. The combination may serve to increase efficacy
(e.g.,
by including in the combination a compound potentiating the potency or
effectiveness of a compound according to the invention), decrease one or more
side effects, or decrease the required dose of the compound according to the
invention.
More particularly, compounds of the invention in combination with modafinil
are useful for the treatment of narcolepsy, excessive daytime sleepiness
(EDS),
Alzheimer's disease, depression, attention-deficit disorders, MS-related
fatigue,
post-anesthesia grogginess, cognitive impairment, schizophrenia, spasticity
associated with cerebral palsy, age-related memory decline, idiopathic
somnolence, or jet-lag. Preferably, the combination method employs doses of
modafinil in the range of about 20 to 300 mg per dose.
In another embodiment, compounds of the invention in combination with
topiramate are useful for the treatment of obesity. Preferably, the
combination
method employs doses of topiramate in the range of about 20 to 300 mg per
dose.
The compounds of the invention are used, alone or in combination with one
or more other active ingredients, to formulate pharmaceutical compositions of
the
18
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
invention. A pharmaceutical composition of the invention comprises: (a) an
effective amount of a compound of Formula (I), or a pharmaceutically
acceptable
salt, pharmaceutically acceptable prodrug, or pharmaceutically active
metabolite
thereof; and (b) a pharmaceutically acceptable excipient.
A "pharmaceutically acceptable excipient" refers to a substance that is non-
toxic, biologically tolerable, and otherwise biologically suitable for
administration to
a subject, such as an inert substance, added to a pharmacological composition
or
otherwise used as a vehicle, carrier, or diluent to facilitate administration
of a
compound of the invention and that is compatible therewith. Examples of
excipients include calcium carbonate, calcium phosphate, various sugars and
types of starch, cellulose derivatives, gelatin, vegetable oils, and
polyethylene
glycols.
Delivery forms of the pharmaceutical compositions containing one or more
dosage units of the compounds of the invention may be prepared using suitable
pharmaceutical excipients and compounding techniques now or later known or
available to those skilled in the art. The compositions may be administered in
the
inventive methods by oral, parenteral, rectal, topical, or ocular routes, or
by
inhalation.
The preparation may be in the form of tablets, capsules, sachets, dragees,
powders, granules, lozenges, powders for reconstitution, liquid preparations,
or
suppositories. Preferably, the compositions are formulated for intravenous
infusion, topical administration, or oral administration.
For oral administration, the compounds of the invention can be provided in
the form of tablets or capsules, or as a solution, emulsion, or suspension. To
prepare the oral compositions, the compounds may be formulated to yield a
dosage of, e.g., from about 0.01 to about 100 mg/kg daily, or from about 0.05
to
about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
Oral tablets may include a compound according to the invention mixed with
pharmaceutically acceptable excipients such as inert diluents, disintegrating
agents, binding agents, lubricating agents, sweetening agents, flavoring
agents,
19
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
coloring agents and preservative agents. Suitable inert fillers include sodium
and
calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar,
glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the
like.
Exemplary liquid oral excipients include ethanol, glycerol, water, and the
like.
Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline
cellulose, and alginic acid are suitable disintegrating agents. Binding agents
may
include starch and gelatin. The lubricating agent, if present, may be
magnesium
stearate, stearic acid or talc. If desired, the tablets may be coated with a
material
such as glyceryl monostearate or glyceryl distearate to delay absorption in
the
gastrointestinal tract, or may be coated with an enteric coating.
Capsules for oral administration include hard and soft gelatin capsules. To
prepare hard gelatin capsules, compounds of the invention may be mixed with a
solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by
mixing the compound of the invention with water, an oil such as peanut oil or
olive
oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty
acids,
polyethylene glycol 400, or propylene glycol.
Liquids for oral administration may be in the form of suspensions, solutions,
emulsions or syrups or may be presented as a dry product for reconstitution
with
water or other suitable vehicle before use. Such liquid compositions may
optionally contain: pharmaceutically-acceptable excipients such as suspending
agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin,
hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the
like); non-aqueous vehicles, e.g., oil (for example, almond oil or
fractionated
coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for
example,
methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as
lecithin; and, if desired, flavoring or coloring agents.
The compounds of this invention may also be administered by non-oral
routes. For example, the compositions may be formulated for rectal
administration
as a suppository. For parenteral use, including intravenous, intramuscular,
intraperitoneal, or subcutaneous routes, the compounds of the invention may be
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
provided in sterile aqueous solutions or suspensions, buffered to an
appropriate
pH and isotonicity or in parenterally acceptable oil. Suitable aqueous
vehicles
include Ringer's solution and isotonic sodium chloride. Such forms will be
presented in unit-dose form such as ampules or disposable injection devices,
in
multi-dose forms such as vials from which the appropriate dose may be
withdrawn,
or in a solid form or pre-concentrate that can be used to prepare an
injectable
formulation. Illustrative infusion doses may range from about 1 to 1000
jig/kg/minute of compound, admixed with a pharmaceutical carrier over a period
ranging from several minutes to several days.
For topical administration, the compounds may be mixed with a
pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug
to
vehicle. Another mode of administering the compounds of the invention may
utilize a patch formulation to affect transdermal delivery.
Compounds of the invention may alternatively be administered in methods
of this invention by inhalation, via the nasal or oral routes, e.g., in a
spray
formulation also containing a suitable carrier.
Exemplary compounds useful in methods of the invention will now be
described by reference to the illustrative synthetic schemes for their general
preparation below and the specific examples that follow. Artisans will
recognize
that, to obtain the various compounds herein, starting materials may be
suitably
selected so that the ultimately desired substituents will be carried through
the
reaction scheme with or without protection as appropriate to yield the desired
product. Alternatively, it may be necessary or desirable to employ, in the
place of
the ultimately desired substituent, a suitable group that may be carried
through the
reaction scheme and replaced as appropriate with the desired substituent.
Unless
otherwise specified, the variables are as defined above in reference to
Formula (I).
Reactions may be performed between the melting point and the reflux
temperature
of the solvent, and preferably between 0 C and the reflux temperature of the
solvent.
21
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
SCHEME A
/--\
Hal OR3R4 R'i ¨N NH R1 N (.r OR3 R
4
HOR3R4
______________________ > \ Om L(,,rNN
__________________________________________________ ,
BrN Br ni
N (5) 0
(3) (4) (I-A)
In some embodiments, compounds of Formula (I) are prepared as shown in
Scheme A. 3-Bromo-pyridines (3), where Hal is bromo, chloro, or fluoro, are
commercially available or prepared using methods known to one skilled in the
art.
Displacement of the Hal substituent is accomplished by reaction with reagents
HOR3R4, in the presence of a suitable base such as NaOH, KOH, K2CO3, Na2CO3,
C52CO3, NaH, or a mixture thereof, in a polar solvent such as N,N-
dimethylformamide (DMF), ethylene glycol dimethyl ether (DME), N,N-
dimethylacetamide (DMA), dimethylsulfoxide (DMSO), acetonitrile, or a mixture
thereof, at a temperature between room temperature and the reflux temperature
of
the solvent, or subject to microwave irradiation, to provide ethers (4).
Transition
metal-catalyzed reaction of bromides (4) with amines (5) and a CO equivalent,
such as CO gas or Mo(C0)6, in the presence of a suitable palladium (II)
catalyst,
and optional additives such as t-Bu3PHBF4+, at a temperature between room
temperature and the reflux temperature of the solvent, or subject to microwave
irradiation, provide compounds of Formula (I) where Y is N and R2 is ¨0R3R4
(Formula I-A). Alternatively, halogen-metal exchange of the bromine atom of
(4)
by treatment with n-BuLi or t-BuLi and quenching with a CO2 equivalent
provides
the corresponding carboxylic acids. Amide coupling of such acids with amines
(5),
in the presence of coupling agents known to one skilled in the art, also
provides
compounds of Formula (I-A). One skilled in the art will recognize that the R1
substitutent may be carried through the sequence as a suitable protecting
group
(such as a tert-butylcarbamoyl, or Boc, group), and installed at a later point
in the
sequence by, for example, reductive amination protocols.
22
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
SCHEME B
Hal1
R N Hal
(5)
N 1 N HOR3R4
A N
_____________________________________________________________ > (I-A)
0 0
(6) (7)
In other embodiments, compounds of Formula (I-A) are prepared as shown
in Scheme B. Amide coupling of pyridine carboxylic acids (6) (where A is OH)
(6)
with amines (5) provides amides (7). Alternatively, acid chlorides (6) (where
A is
Cl) may be reacted with amines (5) in the presence of a suitable base such as
aq.
NaOH, aq. KOH, Et3N, iPr2NEt, Pyridine, or a mixture thereof, in a solvent
such as
CH2Cl2, dichloroethane (DCE), toluene, isopropyl acetate, or a mixture
thereof, to
form amides (7). Displacement of the Hal group as described in Scheme A
provides compounds of Formula (I-A).
SCHEME C
Hal
HOR3R4
r0R3R4
(5)
RxON ____________________________ ,--
RxON _______________________________________________________ x (I-A)
0 0
(16) (17)
In further embodiments, compounds of Formula (I-A) are prepared from
compounds (16), where Rx is methyl or ethyl, and Hal is bromo, chloro, or
fluoro,
according to Scheme C. Displacement of the Hal substituent with a reagent
HOR3R4, as described in Scheme A, gives a compound of formula (17). Reaction
of a compound (17) with an amine (5), in the presence of an organometallic
reagent, such as an alkyl Grignard reagent or alkyllithium reagent, in solvent
such
as tetrahydrofuran (THF), diethyl ether (Et20), methyl tert-butyl ether
(MTBE), 2-
methyl-THF, or a mixture thereof, at a temperature between about 0 C and
about
C, gives a compound of Formula (I-A). Examples of suitable organometallic
reagents include RYMgBr, RYMgCI, or RYLi, where RY is methyl, ethyl, propyl,
isopropyl, butyl, or hexyl. Where a protecting group is used in place of R1,
such a
23
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
protecting group may be removed through standard deprotection methods, and R1
installed by reductive amination protocols.
SCHEME D
1 R1
Th\I
HOR'õ R' N
ORR
34
I Hl ) , I ¨Hal ___ ,
L(,}friNIN L(,,,friNlrN
HO2C1\r 6 a
0 0
(8) (9) (I-B)
Referring to Scheme D, pyridines (8), where the Hal substituent is at the 5-
or 6-position of the pyridine are coupled with amines (5) using general amide
coupling methods to give amides (9). Replacement of the Hal substituent with
-0R3R4 is accomplished by: 1) displacement by HOR3R4 reagents under basic
conditions as described in Scheme A; or 2) Ullmann coupling in the presence of
a
suitable copper (I) catalyst, such as Cul, in a solvent such as DMF, DMSO,
hexamethylphosphoramide (HMPA), or a mixture thereof. The displacement
provides compounds of Formula (I) where Y is CRa, Ra is ¨0R3R4, and R2 is ¨H
or
compounds of Formula (I) where Y is CH and R2 is ¨0R3R4 (Formula I-B).
SCHEME E
Hal Hal Hal
1 1 _E 1
RON _______ ' ROIN ________________ ' HON
1- N
0 0 0 0 (13)
r (10), R = H (12)
.,.. (11), R = Ci_olkyl
i (5) 1 (5)
R1N Hal R1N
Hal
1 1
m N
(,,riiiNI I
N CN
1-
0 0 0
(14) (15)
Compounds of Formula (I) where X is N, Y is CRa, Ra is ¨CN, and R2 is
-0R3R4 (Formula I-C, not shown) may be prepared from cyano amides (15), which
are accessed as shown in Scheme E. Pyridine-2-carboxylic acids (10) are
converted to the N-oxide analogs (12) by reaction with urea-hydrogen peroxide
complex and trifluoroacetic acid anhydride. Installation of the cyano
substituent is
24
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
accomplished by reaction with trimethylsilyl cyanide (TMSCN) and
dimethylcarbamyl chloride to provide nitrile acids (13). Alternatively, acids
(10)
may be esterified according to known methods to give esters (11), which may be
converted to N-oxide esters (12). Following reaction with TMSCN and
dimethylcarbamyl chloride to install the cyano group, hydrolysis of the ester
group
provides acids (13). Acids (13) are converted to cyano amides (15) by amide
coupling with amines (5) as described in Scheme A. Alternatively, N-oxides
(12),
where R is ¨H, may be coupled with amines (5) directly, using amide coupling
methods as described in Scheme A. N-Oxide amides (14) are reacted with
TMSCN and dimethylcarbamyl chloride to give the corresponding cyano amides
(15). Reaction of amides (15) via displacement or Ullmann coupling protocols
as
described in Schemes A and D provide compounds of Formula (I-C). Nitriles (15)
are reduced to the corresponding aminomethyl analogs or hydrolyzed to form the
corresponding acids or amides (not shown).
Those skilled in the art will recognize that several of the chemical
transformations described above may be performed in a different order than
that
depicted in the above Schemes.
Compounds of Formula (I) may be converted to their corresponding salts
using methods known to those skilled in the art. For example, amines of
Formula
(I) may be treated with trifluoroacetic acid (TFA), HCI, maleic acid, or
citric acid in
a solvent such as Et20, CH2Cl2, THF, or methanol (Me0H) to provide the
corresponding salt forms.
Compounds prepared according to the schemes described above may be
obtained as single enantiomers, diastereomers, or regioisomers, by enantio-,
diastero-, or regiospecific synthesis, or by resolution. Compounds prepared
according to the schemes above may alternately be obtained as racemic (1:1) or
non-racemic (not 1:1) mixtures or as mixtures of diastereomers or
regioisomers.
Where racemic and non-racemic mixtures of enantiomers are obtained, single
enantiomers may be isolated using conventional separation methods known to
CA 02706328 2015-04-21
one skilled in the art, such as chiral chromatography, recrystallization,
diastereomeric salt formation, derivatization into diastereomeric adducts,
biotransformation, or enzymatic transformation. Where regioisomeric or
diastereomeric mixtures are obtained, single isomers may be separated using
conventional methods such as chromatography or crystallization.
The following examples are provided to further illustrate the invention and
various preferred embodiments.
EXAMPLES
Chemistry:
In preparing the compounds described in the examples below and obtaining
the corresponding analytical data, the following experimental and analytical
protocols were followed unless otherwise indicated.
Unless otherwise specified, reaction mixtures were magnetically stirred at
room temperature (rt) under a N2(g) atmosphere. Where solutions were "dried,"
they were generally dried over a drying agent such as Na2SO4 or MgSO4. Where
mixtures, solutions, and extracts were "concentrated", they were typically
concentrated on a rotary evaporator under reduced pressure.
Normal phase flash column chromatography (FCC) was typically performed
with RediSep0 silica gel columns using Me0H/DCM or 2 M NH3 in Me0H/DCM as
eluent, unless otherwise indicated.
Reverse phase high performance liquid chromatography (HPLC) was
TM
performed on a Gilson HPLC with an Xterra Prep RP18 (5 pm, 30 x 100 mm)
column, and a gradient of 10 to 99% acetonitrile/water (20 mM NH4OH) over 12
min, and a flow rate of 30 mL/min.
IM
Mass spectra (MS) were obtained on an Agilent series 1100 MSD using
electrospray ionization (ESI) in positive mode unless otherwise indicated.
Calculated (calcd.) mass corresponds to the exact mass.
Nuclear magnetic resonance (NMR) spectra were obtained on Bruker
model DRX spectrometers. The format of the 1H NMR data below is: chemical
26
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
shift in ppm downfield of the tetramethylsilane reference (multiplicity,
coupling
constant J in Hz, integration).
Chemical names were generated using Chem Draw Ultra 6Ø2
(CambridgeSoft Corp., Cambridge, MA).
9
N 0
1\li.r-N
0
Example 1: (4-Isopropyl-piperazin-1-y1)-[6-(tetrahydro-furan-3-yloxy)-pyridin-
3-y1]-
methanone hydrochloride salt.
Step A: 5-Bromo-2-(tetrahydro-furan-3-yloxy)-pyridine. To a solution of 5-
bromo-2-fluoropyridine (1.5 mL, 14.2 mmol) in DMF (14 mL) was added C52CO3
(9.3 g, 28.5 mmol) and 3-hydroxytetrahydrofuran (1.7 mL, 21.3 mmol). The
reaction mixture was heated at 90 C for 3 days then allowed to cool to room
temperature (rt). Water was added and product was filtered off, washed with
water, and dried under vacuum overnight (3.5 g, 100%). MS (ESI): mass calcd.
for C9H10BrNO2, 243.0; m/z found, 244.3, 246.3 [M-1-H]. 1H NMR (CDCI3): 8.17
(d, J = 2.1 Hz, 1H), 7.64 (dd, J = 8.8, 2.6 Hz, 1H), 6.66 (dd, J = 8.7, 0.5
Hz, 1H),
5.52-5.48 (m, 1H), 4.04-3.95 (m, 2H), 3.93-3.86 (m, 2H), 2.30-2.19 (m, 1H),
2.15-
2.08(m, 1H).
Step B. To a vial charged with 5-bromo-2-(tetrahydro-furan-3-yloxy)-
pyridine (0.293 g, 1.2 mmol), Na2CO3 (0.318 g, 3.0 mmol), isopropylpiperazine
(0.143 mL, 1.0 mmol), trans-di-p-acetatobis[2-(di-o-tolylphosphino)benzyl]di-
palladium (II) (Hermann's catalyst; 47 mg, 0.05 mmol), and Mo(C0)6 (132 mg,
0.5
mmol) was added 2 mL of pure water. The reaction mixture was heated in the
microwave for 10 min at 170 C, cooled to rt and filtered through a pad of
diatomaceous earth. The filtrate was diluted with saturated (satd.) aqueous
(aq.)
NaHCO3 and extracted with CH2Cl2. The combined organic layers were dried
27
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
(Na2SO4), filtered and concentrated. The residue was purified by FCC (2 M NH3
in
Me0H/CH2C12) to give the desired product (105 mg, 33%). MS (ESI): mass calcd.
for C17H25N303, 319.2; m/z found, 320.5 [M-1-H]. 1H NMR (CDC13): 8.24 (dd, J =
2.39, 0.6 Hz, 1H), 7.67 (dd, J = 8.5, 2.4 Hz, 1H), 6.76 (dd, J = 8.5, 0.6 Hz,
1H),
5.61-5.56 (m, 1H), 4.07-3.96 (m, 2H), 3.95-3.87 (m, 2H), 3.84-3.39 (m, 4H),
2.79-
2.68 (m, 1H), 2.63-2.44 (m, 4H), 2.33-2.21 (m, 1H), 2.19-2.10 (m, 1H), 1.05
(d, J =
6.5 Hz, 6H). The free base was dissolved in CH2C12 and treated with excess
1.25
M NCI in methanol. The solvent and excess NCI were removed under vacuum to
provide the NCI salt for biological testing.
The compounds in Examples 2-9 were prepared using methods analogous
to those described for Example 1. Yields and analytical data are provided for
the
free base forms.
------
Y/ __ 0\
cNTh1 0
........7N N
0
Example 2: (4-Isopropyl-[1 ,41d iazepan-1-yI)-[6-(tetrahydro-furan-3-yloxy)-
pyrid in-
3-yll-methanone hydrochloride salt.
Yield: 135 mg, 40%. MS (ESI): mass calcd. for C18H27N303, 333.2; m/z
found, 334.5 [M-1-H]. 1H NMR (CDC13): 8.18 (s, 1H), 7.61 (dd, J = 8.5, 2.3 Hz,
1H), 6.71 (d, J = 8.5 Hz, 1H), 5.56-5.51 (m, 1H), 3.99 (dd, J = 10.4, 4.8 Hz,
1H),
3.97-3.91 (m, 1H), 3.91-3.81 (m, 2H), 3.72-3.67 (m, 2H), 3.48-3.42 (m, 2H),
2.95-
2.79 (m, 1H), 2.77-2.71 (m, 1H), 2.66-2.54 (m, 3H), 2.26-2.16 (m, 1H), 2.13-
2.06
(m, 1H), 1.89-1.83 (m, 1H), 1.77-1.69 (m, 1H), 0.98 (d, J = 6.4 Hz, 3H), 0.94
(d, J
= 6.9 Hz, 3H).
28
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
Y
a clo
0
Example 3: (4-Cyclopropyl-[1,4]diazepan-1-y1)46-(tetrahydro-furan-3-yloxy)-
pyridin-3-y11-methanone.
Yield: 22 mg, 6%. MS (ESI): mass calcd. for C18H25N303, 331.19; rrilz
found, 332.5 [M-1-H]. 1H NMR (CDCI3): 8.22 (s, 1H), 7.65 (d, J = 8.3 Hz, 1H),
6.75 (d, J = 8.5 Hz, 1H), 5.60-5.56 (m, 1H), 4.04 (dd, J = 10.4, 4.7 Hz, 1H),
4.02-
3.97 (m, 1H), 3.95-3.86 (m, 2H), 3.77-3.71 (m, 2H), 3.56-3.48 (m, 2H), 2.99-
2.92
(m, 1H), 2.88-2.77 (m, 3H), 2.31-2.21 (m, 1H), 2.18-2.11 (m, 1H), 1.97-1.77
(m,
3H), 0.53-0.34 (m, 4H).
Y
N 0
(........7N 1 N
0
Example 4: (4-Cyclobuty141,41diazepan-1-y1)-[6-(tetrahydro-furan-3-yloxy)-
pyridin-
3-y1]-methanone.
Yield: 132 mg, 38%. MS (ESI): mass calcd. for C19H27N303, 345.2; rrilz
found, 346.6 [M-1-H]. 1H NMR (CDCI3): 8.22 (s, 1H), 7.65 (dd, J = 8.5, 2.4 Hz,
1H), 6.75 (dd, J = 8.6, 0.6 Hz, 1H), 5.60-5.55 (m, 1H), 4.03 (dd, J = 10.4,
4.7 Hz,
1H), 4.02-3.96 (m, 1H), 3.94-3.86 (m, 2H), 3.81-3.72 (m, 2H), 3.57-3.49 (m,
2H),
2.97-2.81 (m, 1H), 2.66-2.58 (m, 1H), 2.54-2.41 (m, 3H), 2.30-2.22 (m, 1H),
2.17-
2.10 (m, 1H), 2.09-1.91 (m, 3H), 1.90-1.56 (m, 5H).
29
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
(..10
N r
NIN
0
Example 5: (4-Isopropyl-piperazin-1-yI)-[6-(3-methyl-oxetan-3-ylmethoxy)-
pyridin-
3-yll-methanone hydrochloride salt.
Step A: 5-Bromo-2-(3-methyl-oxetan-3-ylmethoxy)-pyridine. Yield: 3.5 g,
95%. MS (ESI): mass calcd. for C10H12NO2, 257.01; rniz found, 258.3, 260.3
[M+H]. 1H NMR (CDCI3): 8.19 (dd, J = 2.6, 0.6 Hz, 1H), 7.66 (dd, J = 8.7, 2.6
Hz,
1H), 6.71 (dd, J = 8.7, 0.6 Hz, 1H), 4.63 (d, J = 5.9 Hz, 2H), 4.44 (d, J =
5.9 Hz,
2H), 4.34 (s, 2H), 1.42 (s, 3H).
Step B. Yield: 11 mg, 3%. MS (ESI): mass calcd. for C18H27N303, 333.21;
rniz found, 334.5 [M-1-H]. 1H NMR (CDCI3): 8.25 (dd, J = 2.4, 0.5 Hz, 1H),
7.70
(dd, J = 8.5, 2.4 Hz, 1H), 6.82 (dd, J = 8.5, 0.5 Hz, 1H), 4.64 (d, J = 5.9
Hz, 2H),
4.45 (d, J = 5.9 Hz, 2H), 4.41 (s, 2H), 3.87-3.42 (m, 4H), 2.77-2.71 (m, 1H),
2.66-
2.42 (m, 4H), 1.43 (s, 3H), 1.05 (d, J = 6.5 Hz, 6H).
rpo
-----
ONN 0
0
Example 6: (4-Isopropyl-f1,41diazepan-1-y1)46-(3-methyl-oxetan-3-ylmethoxy)-
pyridin-3-y1]-methanone hydrochloride salt.
Yield: 11 mg, 3%. MS (ESI): mass calcd. for C19H29N303, 347.2; rniz
found, 348.5 [M+H]. 1H NMR (CDCI3): 8.24 (s, 1H), 7.69 (dd, J = 8.5, 1.8 Hz,
1H), 6.81 (d, J = 8.5 Hz, 1H), 4.65 (d, J = 5.9 Hz, 2H), 4.45 (d, J = 5.9 Hz,
2H),
4.40 (s, 2H), 3.81-3.71 (m, 2H), 3.54-3.48 (m, 2H), 3.03-2.77 (m, 2H), 2.74-
2.60
(m, 3H), 1.96-1.87 (m, 1H), 1.72-1.62 (m, 1H), 1.43 (s, 3H), 1.08-0.97 (m,
6H).
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
q 9
ONN 0
N
0
Example 7: (4-Cyclobutyl-[1,4]diazepan-1-y1)-(6-cyclopentyloxy-pyridin-3-y1)-
methanone.
Step A: 5-Bromo-2-cyclopentyloxy-pyridine. Yield: 1.69 g, 82%. MS
(ESI): mass calcd. for C10H12BrNO, 241.01; rniz found, 242.3, 244.3 [M-1-H].
1H
NMR (CDCI3): 8.18 (d, J = 2.5 Hz, 1H), 7.60 (dd, J = 8.8, 2.6 Hz, 1H), 6.59
(d, J =
8.8 Hz, 1H), 5.34-5.30 (m, 1H), 1.99-1.90 (m, 2H), 1.82-1.73 (m, 4H), 1.67-
1.58
(m, 2H).
Step B. Yield: 114 mg, 33%. MS (ESI): mass calcd. for C20H29N302,
343.2; rniz found, 344.6 [M-1-H]. 1H NMR (CDCI3): 8.21 (s, 1H), 7.60 (dd, J =
8.5,
2.4 Hz, 1H), 6.65 (dd, J = 8.5, 0.5 Hz, 1H), 5.40-5.35 (m, 1H), 3.77-3.67 (m,
2H),
3.56-3.47 (m, 2H), 2.91-2.77 (m, 1H), 2.62-2.55 (m, 1H), 2.51-2.36 (m, 3H),
2.06-
1.87 (m, 5H), 1.86-1.70 (m, 7H), 1.69-1.53 (m, 4H).
Eq4
a 0
0
Example 8: (4-Cyclobutyl-[1,4]diazepan-1-y1)-(6-cyclohexyloxy-pyridin-3-y1)-
methanone.
Step A: 5-Bromo-2-cyclohexyloxy-pyridine. Yield: 1.73 g, 79%. MS (ESI):
mass calcd. for C10H14BrNO, 255.03; rniz found, 256.4, 258.4 [M+H]. 1H NMR
(CDCI3): 8.15 (d, J = 2.5 Hz, 1H), 7.60 (dd, J = 8.8, 2.6 Hz, 1H), 6.60 (d, J
= 8.8
Hz, 1H), 4.99-4.93 (m, 1H), 2.02-1.94 (m, 2H), 1.82-1.75 (m, 2H), 1.62-1.54
(m,
31
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
1H), 1.54-1.36 (m, 4H), 1.34-1.24 (m, 1H).
Step B. Yield: 100 mg, 28%. MS (ESI): mass calcd. for C21F131N302,
357.2; rniz found, 358.5 [M-1-H]. 1H NMR (CDCI3): 8.19 (s, 1H), 7.61 (dd, J =
8.5,
2.4 Hz, 1H), 6.67 (dd, J = 8.5, 0.6 Hz, 1H), 5.06-4.99 (m, 1H), 3.77-3.69 (m,
2H),
3.57-3.47 (m, 2H), 2.92-2.78 (m, 1H), 2.63-2.56 (m, 1H), 2.51-2.38 (m, 3H),
2.07-
1.89 (m, 5H), 1.87-1.71 (m, 5H), 1.70-1.35 (m, 7H), 1.32-1.22 (m, 1H).
0
z
q Y
/NM r
\_.........7N N
0
Example 9: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-
pyridin-3-yl]-methanone.
Step A: 5-Bromo-2-(tetrahydro-pyran-4-yloxy)-pyridine. Yield: 2.16 g,
98%. MS (ESI): mass calcd. for C10H12BrNO2, 257.01; rniz found, 258.1, 260.1
[M+H]. 1H NMR (CDCI3): 8.15 (d, J = 2.5 Hz, 1H), 7.63 (dd, J = 8.8, 2.5 Hz,
1H),
6.64(d, J = 8.8 Hz, 1H), 5.20-5.14(m, 1H), 4.01-3.93(m, 2H), 3.60 (ddd, J=
11.9,
9.2, 3.0 Hz, 2H), 2.08-2.01 (m, 2H), 1.81-1.72 (m, 2H).
Step B. Yield: 81 mg, 22%. MS (ESI): mass calcd. for C201-129N303,
359.22; rniz found, 360.6 [M+H]. 1H NMR (CDCI3): 8.21 (s, 1H), 7.65 (dd, J =
8.5, 2.4 Hz, 1H), 6.73 (dd, J = 8.5, 0.6 Hz, 1H), 5.31-5.21 (m, 1H), 4.02-3.94
(m,
2H), 3.78-3.72 (m, 2H), 3.61 (ddd, J = 11.9, 9.1, 2.9 Hz, 2H), 3.57-3.49 (m,
2H),
2.96-2.80 (m, 1H), 2.66-2.58 (m, 1H), 2.54-2.40 (m, 3H), 2.11-1.91 (m, 5H),
1.90-
1.73 (m, 5H), 1.67-1.50 (m, 2H).
32
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
9
Nr-Th 1
N,,NCN
0
Example 10: 6-(4-Cyclopropyl-[1,4]diazepane-1-carbonyl)-3-(tetrahydro-furan-3-
yloxy)-pyridine-2-carbonitrile.
Step A: 5-Bromo-1-oxo-pyridine-2-carboxylic acid. To a 0 C mixture of 5-
bromo-picolinic acid (18.5 g, 91.6 mmol) and urea hydrogen peroxide complex
(18.2 g, 0.194 mol) in acetonitrile (275 mL) was added trifluoroacetic
anhydride (26
mL, 0.187 mol). After 4.5 h, the mixture was treated with aq. Na25203 at 0 C,
stirred for 10 min, and then extracted with CH2Cl2 (300 mL x 5). The combined
organic layers were concentrated to give the crude product, which was
suspended
in boiling water (500 mL) and filtered. The filtered solid was triturated with
boiling
Me0H (500 mL) twice, leaving a yellow solid. The aqueous and methanolic
extracts were combined and concentrated to dryness to give >100% of the acid
as
a tan solid. MS (ESI): mass calcd. for C6H4BrNO3, 216.94; m/z found, 218.1
[M+H]. 1H NMR (d6-DMS0): 17.70 (s, 1H), 9.19 (d, J= 1.5 Hz, 1H), 8.18-8.12
(m, 2H).
Step B: (5-Bromo-1-oxo-pyridin-2-y1)-(4-cyclopropy141,41diazepan-1-y1)-
methanone. A mixture of 5-bromo-1-oxo-pyridine-2-carboxylic acid (10.0 g 45.9
mmol), 1-hydroxybenzotriazole (HOBt; 9.93 g, 73.4 mmol), and 1-(3-
dimethylaminopropy1)-3-ethylcarbodiimide (EDC; 13.4 g, 70.3 mmol) in DMF (300
mL) was stirred for 5 min and then treated with 1-cyclopropy141,4]diazepane
dihydrochloride (12.4 g, 58.4 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU;
21.0 mL, 0.140 mol). After 22 h, the mixture was diluted with 0H2012 and
washed
with 1 N NaOH and water. The organic layer was dried and concentrated. The
residue was purified by FCC to give the title compound (13.2 g, 85%). MS
(ESI):
mass calcd. for C14H18BrN302, 339.06; m/z found, 340.2 [M-1-H].
33
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
Step C: 3-Bromo-6-(4-cyclopropyl-[1,4]diazepane-1-carbonyl)-pyridine-2-
carbonitrile. A mixture of (5-bromo-1-oxo-pyridin-2-y1)-(4-cyclopropyl-
[1,4]diazepan-1-y1)-methanone (13.1 g, 38.8 mmol), TMSCN (26.0 mL, 195 mmol),
and dimethylcarbamyl chloride (18.0 mL, 195 mmol) was heated at 50 C for 16
h.
The mixture was allowed to cool to rt and was poured over ice water containing
NaOH. The mixture was extracted with CH2Cl2 (2x), and the combined organic
layers were dried and concentrated to give the crude product. The crude
material
was purified by FCC to give the title compound (13.6 g, 76%). MS (ESI): mass
calcd. for C15H17BrN40, 348.06; m/z found, 349.6 [M-1-H]. 1H NMR (d6-acetone):
8.42 (d, J= 8.4 Hz, 1H), 7.83-7.81 (m, 1H), 3.70-3.68 (m, 2H), 3.55-3.52 (m,
2H),
2.93-2.91 (m, 1H), 2.87-2.80 (m, 3H), 1.96-1.87 (m, 2H), 1.84-1.80 (m, 1H),
0.46-
0.44 (m, 1H), 0.43-0.41 (m, 1H), 0.37-0.35 (m, 1H), 0.32-0.30 (m, 1H).
Step D. A mixture of 3-bromo-6-(4-cyclopropyl-[1,4]diazepane-1-carbonyl)-
pyridine-2-carbonitrile (0.600 g, 1.71 mmol), 3-hydroxytetrahydrofuran (301
mg,
3.41 mmol), and anhydrous 052003 (1.67 g, 5.13 mmol) in DMSO (7 mL) was
heated by microwave irradiation at 150 C for 35 min. The mixture was diluted
with water and extracted with Et20. The combined organic layers were dried
(Na2CO3) and concentrated. The residue was purified by FCC to give the title
compound (280 mg, 46%). MS (ESI): mass calcd. for C19H24N403, 356.4; m/z
found, 357.5 [M-1-H]. 1H NMR (CDCI3): 7.94 (d, J = 8.8 Hz, 1H), 7.35 (d, J =
8.9
Hz, 1H), 5.08-5.04 (m, 1H), 4.12-3.93 (m, 4H), 3.77-3.72 (m, 2H), 3.69-3.63
(m,
2H), 2.98-2.92 (m, 2H), 2.87-2.81 (m, 2H), 2.35-2.25 (m, 1H), 2.25-2.18 (m,
1H),
1.97-1.83 (m, 3H), 0.51-0.35 (m, 4H).
The compounds in Examples 11-12 were prepared using methods
analogous to those described for Example 10.
34
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
9
Nr---) 1
1 0
\._=.,=,7.- , INCN
0
Example 11: 3-Cyclopentyloxy-6-(4-cyclopropyl-[1,4]diazepane-1-carbonyl)-
pyridine-2-carbonitrile.
Yield: 33 mg, 5%. MS (ESI): mass calcd. for C201-126N402, 354.4; rniz
found, 355.5 [M+H]. 1H NMR (CDCI3): 7.92 (d, J = 8.9 Hz, 1H), 7.40 (d, J = 8.9
Hz, 1H), 4.93-4.88 (m, 1H), 3.78-3.73 (m, 2H), 3.71-3.65 (m, 2H), 2.98-2.92
(m,
2H), 2.87-2.81 (m, 2H), 1.99-1.84 (m, 9H), 1.75-1.65 (m, 2H), 0.51-0.36 (m,
4H).
4
N 1 0
\------n-rNCN
0
Example 12: 3-Cyclohexyloxy-6-(4-cyclopropyl-[1,4]diazepane-1-carbonyl)-
pyridine-2-carbonitrile.
Yield: 98 mg, 15%. MS (ESI): mass calcd. for 021H28N402,368.4; rniz
found, 369.6 [M-1-H]. 1H NMR (CDCI3): 7.88 (d, J = 8.9 Hz, 1H), 7.39 (d, J =
9.0
Hz, 1H), 4.49-4.43 (m, 1H), 3.75-3.70 (m, 2H), 3.69-3.62 (m, 2H), 2.96-2.90
(m,
2H), 2.85-2.79 (m, 2H), 1.97-1.78 (m, 7H), 1.74-1.64 (m, 2H), 1.59-1.50 (m,
1H),
1.46-1.35 (m, 3H), 0.49-0.33 (m, 4H).
The compounds in Examples 13-39 may be prepared using methods
analogous to those described in the preceding examples.
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
0
Y
\,.........rNIN
0
Example 13: (4-lsopropyl-[1,4]diazepan-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-
pyridin-3-y11-methanone.
0
Y
\_.......,yNI. N
0
Example 14: (4-Cyclopropyl-f1,41diazepan-1-y1)-[6-(tetrahydro-pyran-4-yloxY)-
pyridin-3-y1]-methanone.
0
Y
0
Example 15: (4-Cyclopentyl-[1,4]diazepan-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-
pyridin-3-y11-methanone.
0
Y
N 0
1\11.rN
0
36
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
Example 16: (4-lsopropyl-piperazin-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-pyridin-
3-
y1]-methanone.
0
&N
Y
1\11.rN
0
Example 17: (4-Cyclopropyl-piperazin-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-
pyridin-
3-y1]-methanone.
0
Y
\1113N o
N I N
0
Example 18: (4-Cyclobutyl-piperazin-1-y1)-[6-(tetrahydro-pyran-4-yloxy)-
pyridin-3-
yll-methanone.
0
Y
aõ o
N,rrN
0
Example 19: (4-Cyclopentyl-piperazin-1-y1)46-(tetrahydro-pyran-4-yloxy)-
pyridin-
3-y1]-methanone.
37
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
0
Y
0-Nn 1
, 0
0
Example 20: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[5-(tetrahydro-pyran-4-yloxy)-
pyridin-2-y11-methanone.
0¨Nn
1
\_..........7NNO)
0
Example 21: (4-Cyclobutyl-f 1 ,41d iazepan-1-y1)46-(tetrahydro-pyran-4-yloxy)-
pyrid in-2-yI]-methanone.
.
0-NrTh rC)
0
Example 22: (6-Cyclobutoxy-pyridin-3-y1)-(4-cyclobutyl-[1,4]diazepan-1-y1)-
methanone.
Q
Nn (C)
\_..........,N IN
0
Example 23: (4-Cyclobutyl-f 1 ,41d iazepan-1-y1)46-(oxepan-4-yloxy)-pyrid in-3-
y11-
methanone.
38
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
0¨NIM
IN
0
Example 24: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(oxepan-3-yloxy)-pyridin-3-
y11-
methanone.
0¨NrTh rzC)
0
Example 25: (4-Cyclobutyl-f1,41diazepan-1-y1)-(6-cyclobutylmethoxy-pyridin-3-
y1)-
methanone.
(L\
0
0¨NrTh
0
Exmaple 26: (4-Cyclobutyl-f1,41diazepan-1-y1)-(6-cyclopropylmethoxy-pyridin-3-
yl)-methanone.
NIM rc:1
0
Example 27: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(tetrahydro-thiophen-3-yloxy)-
pyridin-3-yll-methanone.
39
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
S
Y
0-NrTh rr
\_......._7NN
0
Example 28: (4-Cyclobutyl-f1,41diazepan-1-y1H6-(tetrahydro-thiopyran-4-yloxy)-
pyridin-311]-methanone.
/
i)
0¨ NrTh
0
Example 29: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(1 -methyl-pyrrol id in-3-
yloxy)-
pyrid in-3-yll-methanone.
c:1______
y
0¨ Nn
0
Example 30: 1-{3-[5-(4-Cyclobutyl-[1,4]diazepane-1-carbonyl)-pyridin-2-yloxy]-
pyrrolidin-1-ylyethanone.
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
gS
0-NIM 0
0
Example 31: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(thiepan-3-yloxy)-pyridin-3-
y11-
methanone.
c )
0¨ Nn0
\...,.....,N N
0
Example 32: (4-Cyclobutyl-[1,4]cl iazepan-1-yI)-[6-(th iepan-4-yloxy)-pyrid in-
3-yI]-
methanone.
I
N
0-- Nn o
\_.......,yNN
0
Example 33: (4-Cyclobutyl-[1,41diazepan-1-y1H6-(1 -methyl-piperidin-4-yloxy)-
pyridin-3-y1]-methanone.
41
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
C)
z
0-Nn
0
Example 34: 1-{4-[5-(4-Cyclobutyl-[1,4]diazepane-1-carbonyl)-pyridin-2-yloxyl-
piperidin-1-ylyethanone.
Cr5
0-NrTh (C)
0
Example 35: (4-Cyclobutyl-[1,4]diazepan-1-y1)46-(1-isopropyl-azepan-4-yloxy)-
pyridin-3-y11-methanone.
ci5
NIM 0
N
0
Example 36: 1-{4-[5-(4-Cyclobutyl-[1,4]diazepane-1-carbonyl)-pyridin-2-
yloxyl-
azepan-1-yll-ethanone.
42
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
qN
0¨NIM r()
0
Example 37: (4-Cyclobutyl-[1,4]diazepan-1-y1)-[6-(1 -ethyl-azepan-3-yloxy)-
pyridin-
3-y11-m etha none.
_____________________________ 0
gN
N
0
Example 38: 1-{3-f5-(4-Cyclobutyl-f 1 ,41d iazepane-1-carbonyl )-pyrid in-2-
yloxyl-
azepan-1-y1}-ethanone.
&N (rC)
N
0
Example 39: (4-Cyclopropyl-piperazin-1-y1)-[6-(tetrahydro-pyran-3-yloxy)-pyrid
in-
3-yll-m etha none.
0
/NM 0
N N
0 =FICI
43
CA 02706328 2010-05-19
WO 2009/067401 PCT/US2008/083764
Example 40: (4-Cyclobutyl-[1,4]diazepan-1-y1)46-(tetrahydro-pyran-4-
yloxy)-
pyridin-3-y11-methanone=HCI. To a solution of (4-cyclobutyl-[1,4]diazepan-1-
y1)46-
(tetrahydro-pyran-4-yloxy)-pyridin-3-y1]-methanone (6.17 g, 17.2 mmol) in IPA
(100
mL) was added anhydrous HCI (5-6 M solution in IPA, 3.44 mL, 17.2 mmol). The
mixture was then warmed to 80 C and cooled to 60 C to promote precipitation.
Seed crystals were added at this point. Cooling to room temperature,
filtering,
washing with IPA (50 mL), and drying at 50 C provided the title compound as a
white crystalline solid (5.29 g, 78% yield). 1H -NMR: (400MHz, DMSO) 6, 11.46
(bs, 1H), 8.29 (bs, 1H), 7.82 (bd, J= 7.6 Hz, 1H), 6.86 (d, J= 8.8 Hz, 1H),
5.22 (m,
1H), 4.18-3.22 (m, 11H), 3.10-2.90 (m, 2H), 2.48-2.25 (m, 3H), 2.25-1.97 (m,
5H),
1.78-1.59 (m, 4H). Anal. Calcd for 0201-1300IN303: C, 60.67; H, 7.64; N,
10.61; Cl,
8.95, found 0,60.71; H, 7.90; N, 10.50; Cl, 8.88.
Biological Methods:
H3 receptor binding (human)
Binding of compounds to the cloned human H3 receptors, stably expressed
in SK-N-MC cells, was performed as described by Barbier, A.J. et al. (Br. J.
Pharmacol. 2004, 143(5), 649-661).
H3 receptor binding (rat)
A rat brain without cerebellum (Zivic Laboratories Inc., Pittsburgh, PA) was
homogenized in 50 mM Tris-HCl/5 mM EDTA and centrifuged at 1,000 rpm for 5
min. The supernatant was removed and recentrifuged at 15,000 rpm for 30 min.
Pellets were rehomogenized in 50 mM Tris/5 mM EDTA (pH 7.4). Membranes
were incubated with 0.8 nM N-[3H]-a-methylhistamine plus/minus test compounds
for 60 min at 25 C and harvested by rapid filtration over GF/C glass fiber
filters
(pretreated with 0.3% polyethylenimine) followed by four washes with buffer.
Nonspecific binding was defined in the presence of 100 pM histamine.
Inhibitory
concentration (responsible for 50% inhibition of maximal effect, 1050) values
were
determined by a single site curve-fitting program (Graph Pad, San Diego, CA)
and
44
CA 02706328 2010-05-19
WO 2009/067401
PCT/US2008/083764
converted to K, values based on a N43F1]-a-methylhistamine dissociation
constant
(Kd) of 0.8 nM.
Cyclic AMP accumulation
Sublines of SK-N-MC cells were created that expressed a reporter
construct and either the human or rat H3 receptor. The pA2 values were
obtained
as described by Barbier et al. (2004).
Data for compounds tested in the above assays are presented in Table 1 as
an average of the results obtained (NT = not tested).
Table 1
Ex. Human H3 Ki (nM) Rat H3 Ki (nM) Human pA2 Rat
pA2
1 104 NT NT NT
2 9.0 NT NT NT
3 6.8 NT NT NT
4 1.3 58 9.48 7.84
5 5010 NT NT NT
6 37 NT NT NT
7 1.1 44 9.31 8.32
8 0.8 17 8.98 8.01
9 0.9 28* 9.63 8.36
21 NT NT NT
11 6.0 NT NT NT
12 2.2 NT NT NT
10 * Compound tested as the trifluoroacetic acid salt.
